Agilon Health upgraded to Neutral from Sell at Citi

Citi upgraded Agilon Health (AGL) to Neutral from Sell with a price target of $2.25, up from $1.75. The firm sees limited further downside to the shares and is incrementally more positive on the Medicare Advantage space. While Agilon’s business still faces significant risks in 2025, particularly around contract renegotiations, the risks are now accurately reflected in the stock price and Citi does not see much more room for downside, the analyst tells investors in a research note.